The Patent Finder

Genextra S.P.A.

Also on record
Records under this name other than patents Genextra S.P.A. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.

Showing 1 to 6 of 6 · Back to Genextra S.P.A.

PatentTitleStatus Expires Confidence
US 8,592,444Spirocyclic derivatives as histone deacetylase inhibitors
Lapsed on the fee record
Ended Nov 26, 2025 · From the USPTO record
Lapsed on the fee recordEnded Nov 26, 2025From the USPTO record
US 8,242,175Class of histone deacetylase inhibitors
Lapsed on the fee record
Ended Aug 14, 2024 · From the USPTO record
Lapsed on the fee recordEnded Aug 14, 2024From the USPTO record
US 8,058,273Histone deacetylases inhibitors
Lapsed on the fee record
Ended Nov 15, 2023 · From the USPTO record
Lapsed on the fee recordEnded Nov 15, 2023From the USPTO record
US 9,115,148Spirocyclic derivatives as histone deacetylase inhibitors
Lapsed on the fee record
Ended Aug 25, 2023 · From the USPTO record
Lapsed on the fee recordEnded Aug 25, 2023From the USPTO record
US 8,980,877Spirocyclic derivatives as histone deacetylase inhibitors
Lapsed on the fee record
Ended Mar 17, 2023 · From the USPTO record
Lapsed on the fee recordEnded Mar 17, 2023From the USPTO record
US 7,803,800Histone deacetylases inhibitors
Lapsed on the fee record
Ended Sep 28, 2022 · From the USPTO record
Lapsed on the fee recordEnded Sep 28, 2022From the USPTO record
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited